/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Risk Factors and the notes to the consolidated financial statements in Part II, Item 8. You should carefully consider these risks before making any investment decisions in us.
$72.27
+$1.16 (+1.63%)
EOD Sep 1, 2026
Revenue grew 12.1%, still solid. Free cash flow declined 215% despite revenue growth, conversion is weakening.
Free cash flow declined 215% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -$57M. The business is consuming cash, not generating it.
20.9x earnings. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$432M
▲ +12.1% YoY
Net Income (TTM)
$167M
▲ +3.0% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (FY)
-$57M
▼ -215.3% YoY
Op. Cash Flow (TTM)
$249M
▲ +13.9% YoY
Net Debt
$411M
Cash & Equiv.
$30M
5Y CAGR: +2.5%
Continue Research
SourceComputed from the 10-Q filed 10 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 11 Aug 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 20.9, National Health Investors (NHI)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in .
On quality, National Health Investors scores 56/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 5.0%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
National Health Investors scores 56 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a mixed business on these measures. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, National Health Investors pays a regular dividend of about $3.62 per share per year (typically in quarterly installments), a yield of roughly 5.0% at the current price. That is a payout ratio of about 105.3% of earnings, so the dividend is stretched at this level. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For NHI's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh NHI's valuation and scores 56/100 on quality (mixed). It also yields about 5.0%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.